

**DIVI'S LABORATORIES LIMITED**

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2017

(₹ in Lakhs)

	Particulars	Quarter ended			Year ended
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		(Unaudited)	(Audited)*	(Unaudited)	(Audited)
<b>1</b>	<b>Revenue from operations</b>	<b>82120</b>	106667	101719	406577
<b>2</b>	Other Income	<b>2968</b>	2093	1631	7598
<b>3</b>	<b>Total Revenue from Operations (1+2)</b>	<b>85088</b>	108760	103350	414175
<b>4</b>	<b>Expenses</b>				
	a) Cost of materials consumed	<b>32152</b>	43620	37115	156319
	b) Purchases of stock-in-trade	<b>0</b>	0	0	0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>1007</b>	(1517)	1404	(2161)
	d) Employee benefits expense	<b>9534</b>	9994	9605	45915
	e) Depreciation and amortization expense	<b>3231</b>	3144	3012	12326
	f) Finance Costs	<b>49</b>	104	38	225
	g) Other Expenses	<b>14945</b>	18370	13220	62728
	<b>Total expenses</b>	<b>60918</b>	73715	64394	275352
<b>5</b>	<b>Profit before exceptional Items and tax (3-4)</b>	<b>24170</b>	35045	38956	138823
<b>6</b>	Exceptional items	<b>0</b>	0	0	0
<b>7</b>	<b>Profit before Tax (5-6)</b>	<b>24170</b>	35045	38956	138823
<b>8</b>	Tax Expense				
	a) Current Tax	<b>4827</b>	4752	8074	28523
	b) Deferred Tax	<b>1689</b>	4364	701	4973
	<b>Total Tax Expense</b>	<b>6516</b>	9116	8775	33496
<b>9</b>	<b>Net Profit for the period (7-8)</b>	<b>17654</b>	25929	30181	105327
<b>10</b>	Other Comprehensive Income: Items that will not be reclassified to Profit or Loss: - Remeasurement of post-employment benefit obligation (net of tax)	<b>(36)</b>	20	(65)	(140)
<b>11</b>	<b>Total comprehensive Income for the period (9+10)</b>	<b>17618</b>	25949	30116	105187
<b>12</b>	Paid-up Equity Share Capital (Face Value: Rs.2 per share)	<b>5309</b>	5309	5309	5309
<b>13</b>	Other Equity				535582
<b>14</b>	<b>Earnings per Share (of Rs.2/- each) (not annualized)</b>				
	a) Basic	<b>6.65</b>	9.77	11.37	39.68
	b) Diluted	<b>6.65</b>	9.77	11.37	39.68



*(Handwritten Signature)*



**NOTES:**

1. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 22<sup>nd</sup> July, 2017.
2. Results for the quarter ended 30<sup>th</sup> June 2017 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
4. The format for un-audited quarterly results as prescribed in SEBI's Circular No.CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5<sup>th</sup> July, 2016, Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
5. \* Figures for the quarter ended 31.03.2017 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the financial year.
6. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
7. Figures for the previous year/period have been regrouped wherever necessary.
8. Details of forex gain/(loss) are given below:

(₹ in Lakhs)

Particulars	Quarter ended 30.06.2017	Quarter ended 31.03.2017	Quarter ended 30.06.2016	Year ended 31.03.2017
Forex gain/(loss)	701	(2904)	73	(3910)

Place: Hyderabad  
Date: 22<sup>nd</sup> July, 2017



for Divi's Laboratories Limited

  
Dr. Murali K. Divi  
Chairman & Managing Director





## INDEPENDENT AUDITOR'S REVIEW REPORT

**TO**  
**THE BOARD OF DIRECTORS**  
**DIVI'S LABORATORIES LIMITED**

We have reviewed the unaudited financial results of **DIVI'S LABORATORIES LIMITED** ("the Company") for the quarter ended **30<sup>th</sup> June, 2017** which are included in the accompanying 'Statement of Standalone Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2017' together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initialled by us for identification purpose. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.


**For P.V.R.K. NAGESWARA RAO & Co.,**  
**Chartered Accountants**

**Firm's Registration Number: 002283S**

*N. Anka Rao*  
**N. ANKA RAO**

**Partner**

**Membership Number: 23939**



**HYDERABAD**  
**22.07.2017**